logo
Heineken shares slide as tariff uncertainties spook investors

Heineken shares slide as tariff uncertainties spook investors

CTV News28-07-2025
FILE - Bottles of Heineken beer are photographed in Washington, USA, March 30, 2018. Dutch brewer Heineken has completed its withdrawal from Russia, 18 months after Moscow launched its full-scale invasion of Ukraine, selling its business in Russia for just 1 euro, the company announced Friday, Aug. 25, 2023. (AP Photo/J. David Ake, FILE)
LONDON — Dutch brewer Heineken's shares slid over 8 per cent on Monday as a forecast-beating profit rise was eclipsed by investor worries over second-half profits and volumes, which Heineken warned may be softer as tariffs weigh on confidence.
The world's No.2 brewer welcomed a trade deal struck between the European Union and the United States and said on Monday that it was weighing all options to deal with growing tariff challenges in the long term, including shifting manufacturing.
Its shares closed down 8.45 per cent despite a 7.4 per cent rise in first-half profit, above analyst estimates, for which it credited growth in once-difficult regions like Africa and Asia as well as cost savings. Beer sales volumes, however, dipped 1.2 per cent.
Analysts and investors pointed to Heineken's warning that volumes would be softer than expected for the remainder of the year as U.S. President Donald Trump's trade salvos disrupt markets in the Americas. A price dispute with retailers meanwhile dented sales in Europe.
The company exports beer, especially its namesake lager, to the U.S. from Europe and Mexico, and has also suffered from the indirect impact on consumer confidence in key markets like Brazil.
CEO Dolf van den Brink welcomed the certainty brought by the trade deal clinched on Sunday, which reduced a threatened 30 per cent U.S. tariff on EU goods to 15 per cent - a rate that would still hit Heineken's U.S. profits.
While some in the industry, such as spirits makers, are hopeful for an exemption, this does not appear to be a prospect for beer.
All options are being considered to mitigate tariffs long-term, including shifting manufacturing, he said, but added that such moves were capital intensive and would first need more consistency in policy.
'We look at all options from ... continuing with our current setup, a more hybrid version, or otherwise,' he told journalists on a call. 'If and when we deem them financially to be more attractive in the mid- to long-term, we would for sure explore them.'
LINGERING TARIFF FEARS, ECONOMIC UNCERTAINTY
Heineken still faces U.S. tariffs of up to 30 per cent on products it produces in Mexico unless the Mexican government can reach an agreement with Washington ahead of an August 1 deadline.
Executives told journalists that since the first quarter, Heineken has also seen economic uncertainty hit spending and confidence in the U.S., Brazil and Mexico.
In Mexico, remittances from the U.S. have fallen significantly, impacting beer industry sales. And U.S. Hispanic consumers were also spending less, van den Brink said.
Heineken continues to expect annual profit growth of between 4 per cent and 8 per cent.
The company also beat forecasts for second quarter revenue and volume, with growth in markets like Vietnam and India, and increased an annual cost-saving goal by a quarter to 500 million euros ($586 million).
'They have slightly downgraded their volume guidance,' said Ryann Dean, global analyst at Heineken investor Aylett Fund Managers. 'Given everything going on in the world... that to me doesn't feel like a terrible outcome.'
Heineken's strong growth in markets like India and China, and consistent profitability, more than offset this, he continued, adding that emerging markets would drive Heineken's long-term volume growth.
Brokerage Jefferies also expressed surprise at the sharp share price fall, which it said was down to worries over softer sales and slower second-half profit growth.
'This represents an attractive buying opportunity in our view, given volume reassurance and profit delivery underpinned by delivery on the cost program,' it said in a note.
(Reporting by Emma Rumney; Editing by Lincoln Feast and Joe Bavier, Kirsten Donovan and Nick Zieminski)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TrueCar (TRUE) Q2 Revenue Jumps 12%
TrueCar (TRUE) Q2 Revenue Jumps 12%

Globe and Mail

timean hour ago

  • Globe and Mail

TrueCar (TRUE) Q2 Revenue Jumps 12%

Key Points GAAP revenue climbed 12.4% year-over-year in Q2 2025, beating expectations and marking TrueCar's best quarter since Q3 2021. GAAP earnings per share for Q2 2025 came in far below analyst forecasts, highlighting persistent profitability challenges. GAAP gross margin declined sharply to 76.3% in Q2 2025, while non-GAAP free cash flow remained negative at ($4.8 million) despite operational improvements. These 10 stocks could mint the next wave of millionaires › TrueCar (NASDAQ:TRUE), a digital automotive marketplace connecting car buyers with certified dealers, released its earnings report for the second quarter of fiscal 2025 on August 6, 2025. The most important takeaway was GAAP revenue was $47.0 million, exceeding analyst expectations by $2.35 million, but offset by a significant net loss and a severe miss on earnings per share; GAAP EPS was ($7.60), well below the estimated ($0.06). The period saw substantial progress in product innovation and customer experience, but ongoing margin pressure and cash burn tempered the positive headline numbers. Overall, the quarter delivered strong GAAP sales growth but did not meet expectations for profitability. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) ($7.60) ($0.06) N/A N/A Revenue (GAAP) $47.0 million $44.65 million $41.8 million 12.4% Net Loss ($7.6 million) ($13.5 million) 43.7% Adjusted EBITDA ($1.2 million) $0.1 million N/A Free Cash Flow ($4.8 million) ($3.6 million) (33.3%) Source: Analyst estimates for the quarter provided by FactSet. Business Overview and Recent Key Focus Areas TrueCar is known for its online platform that streamlines the car-buying process by helping consumers research, compare, and connect with certified auto dealers. The company leverages proprietary data and analytics to offer transparent vehicle pricing, digital purchasing options, and dealer connection features. In recent periods, TrueCar has prioritized expanding its end-to-end online retailing solution, TrueCar+, and investing in product innovation for both dealers and consumers. The rollout of new data-driven tools and automation features reflects TrueCar's emphasis on technological capability, efficiency, and adapting to regulatory requirements. Key success factors include sustained partnerships, expanding coverage of OEM incentive programs, and maintaining a robust affinity network of over 250 partners to drive high-value leads to dealer clients. Quarterly Highlights: Revenue Growth, Operational Trends, and Product Advances In the second quarter, GAAP revenue rose 12.4% year-over-year, outperforming analyst projections and delivering the highest quarterly result since Q3 2021. While monetization per unit increased to $526 (from $468 a year ago), a notable achievement, unique visitor traffic declined from 7.7 million to 5.5 million. This drop was partly due to a deliberate reduction in lower-intent marketing, with the stated aim of boosting quality and conversion efficiency. GAAP gross margin contracted from 86.9% in Q2 2024 to 76.3% in Q2 2025, reflecting increased spending on lower-margin products and higher expenses in scaling new initiatives. Non-GAAP adjusted EBITDA fell to ($1.2 million), compared to a slight gain in the previous year. Non-GAAP free cash flow remained negative, though improved sequentially, with a net outflow of ($4.8 million). Key product developments included enhancements to the dealer platform, such as the launch of 'Actionable Insights,' a tool offering data-driven recommendations to dealers for improved performance. Machine learning was applied via the new "Motivated Buyer" feature, flagging high-intent leads. On the consumer side, TrueCar revamped its search results and vehicle detail pages, making the digital shopping journey more transparent and intuitive, and piloted new features within TrueCar+ to boost user engagement and drive higher conversion rates. Connections with OEM partners remained strong, and incentive-driven programs contributed $2.9 million in revenue in the first half of 2025, already surpassing the $2.5 million received in all of 2024. However, some incentive programs were paused after exceeding budgets at the end of Q2 2025, which could result in revenue lumpiness in coming quarters. Industry data shows TrueCar's new vehicle unit sales grew 6.2% year-over-year in Q2 2025, outpacing the broader market's 2.8% growth and reflecting solid franchise dealer momentum despite ongoing contraction among independent dealer partners. Operational Metrics, Segment Trends, and Competitive Positioning Dealer revenue grew 12.1%, led by franchise dealer stability (up 1.1%) and exceptional gains from vehicle sourcing products (up 264.7%) in Q2 2025. OEM segment revenue increased 19.7% year-over-year. Despite stable new car segment results, overall dealer count dropped from 11,474 in Q2 2024 to 11,177 in Q2 2025, mainly due to headwinds among independent dealers. TrueCar's affinity partner channel—the network of large brands and organizations driving traffic to its platform—continued to deliver high-value leads, though certain OEM incentive programs were paused as a result of faster-than-expected budget use. Efficiency efforts were evident in a sharp 41.8% improvement in funnel conversion year-over-year in Q2 2025, with the average cost per sale on falling 29.9% year-over-year to $169. OpEx lines reflected a mixed picture: sales and marketing spending grew year-over-year but was flat from last quarter, while tech and G&A (general and administrative) expenses declined as cost controls deepened. GAAP gross profit in dollar terms slipped year-over-year despite higher revenue, a symptom of the lower-margin product mix and incremental growth costs. Management expects recent headcount reductions and sales and service team consolidation to yield about $500,000 a month in cost savings beginning in Q3 2025. TrueCar+—the company's digital retailing platform enabling fully online car-buying—remained a standout area of innovation. The integration of dealer management system (DMS) tools and a redesigned online checkout delivered significant metrics improvements in Q2 2025, including a 115% increase in add-to-cart rates, a 40% rise in daily credit application submissions, and a doubling of F&I (finance and insurance) product attachment rates. These signals point to improving customer engagement and growing traction with digital retailing as dealers and consumers continue shifting online. Some challenges remained evident. Unique visitor count dropped by 28.6% year-over-year, reflecting TrueCar's tighter focus on quality leads and conversion at the expense of traffic scale. Dealer sentiment, according to the Cox Automotive Dealer Sentiment Index, declined. Franchise dealers were less affected than independents, which aligns with the sharper decline in independent dealer participation. Inventory trends will bear continued attention as tariffs and affordability put new car supply and pricing under pressure in the second half of the year. Looking Ahead: Outlook and Considerations for Investors TrueCar's management did not issue formal financial guidance for the next quarter or for the remainder of fiscal 2025, citing persistent uncertainty in the automotive market related to tariffs, supply constraints, and evolving OEM incentive strategies. Although executives expressed confidence in the company's ability to navigate diverse growth scenarios, they declined to forecast specific revenue or profit targets. In management's words: 'we believe that the steps we have taken to eliminate costs and maximize our financial flexibility position us to navigate a range of revenue growth scenarios and deliver Adjusted EBITDA profitability and positive Free Cash Flow over the second half of 2025.' Key areas to watch in upcoming quarters include the continued rollout and scaling of TrueCar+, stabilization in unique visitor traffic and dealer count, further improvements in expense control, and potential swings in OEM-driven revenue streams. Persistent negative free cash flow and gross margin compression remain core risks, requiring progress toward sustainable profitability to support long-term competitive standing. TRUE does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Pulmatrix (PULM) Q2 Revenue Falls 100%
Pulmatrix (PULM) Q2 Revenue Falls 100%

Globe and Mail

timean hour ago

  • Globe and Mail

Pulmatrix (PULM) Q2 Revenue Falls 100%

Key Points GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a substantial reduction in R&D activity. Pulmatrix focused on finalizing its merger with Cullgen and pursuing asset divestitures; no forward financial guidance was provided. These 10 stocks could mint the next wave of millionaires › Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025. Net loss per share (GAAP) was $(0.42), compared to $(1.59) in Q2 2024. There were no Wall Street analyst estimates available this quarter, but the reported GAAP loss per share of $(0.42) represented a substantial narrowing from last year's GAAP result of $(1.59) in Q2 2024, mainly due to a near-total reduction in research and development spending. The quarter highlights Pulmatrix's strategic pivot: winding down its prior clinical business, trimming operational costs, conserving cash, and focusing on completing its merger with Cullgen. The company offered no forward guidance for upcoming quarters as it transitions operations. Business Overview and Recent Areas of Focus Pulmatrix's core business has centered on developing inhaled therapies using its proprietary iSPERSE™ technology—a dry powder drug delivery platform aimed at improving medication delivery to the lungs. This platform was designed to increase efficiency and tolerability in treatments compared to traditional inhalers or oral medications, positioning the company in the respiratory therapeutics space. Over the past year, Pulmatrix's strategic priorities have shifted dramatically. It has halted most clinical operations, halted R&D spending, and now seeks to divest its iSPERSE™ intellectual property and remaining clinical assets. The company's ongoing viability depends on successfully completing its pending merger with Cullgen and monetizing its assets or securing royalty streams from former drug candidates such as PUR1900. Key success factors now rest less on product development and more on the execution of these strategic transactions. Quarter Highlights: Operations, Finances, and Pipeline Progress The quarter reflected a sharp operational downsizing as Pulmatrix's GAAP revenue dropped from $1.6 million in Q2 2024 to zero. This change resulted from the completion of the wind-down of its PUR1900 clinical trial. Former sources of operating income, such as milestone payments or funding for joint studies, concluded, and there were no new business or sales streams to replace them during the period. Research and development expense (GAAP) decreased from $2,834,000 in Q2 2024 to $14,000, a 99.5% drop. This near-total reduction in research spending came as Pulmatrix finished closing its flagship clinical programs and terminated related staff. The company stated: 'The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.' Helped by layoffs and cuts, although these savings were partially offset by legal and advisory expenses linked to the merger process. Net loss and operating loss (GAAP) both narrowed substantially. The reduced losses were primarily due to a sharp decrease in R&D expenses. Net loss (GAAP) dropped to $(1.55) million from $(5.81) million in Q2 2024. The company avoided any unusual charges this quarter, whereas the prior period had included a significant loss from an asset transaction with MannKind. With its extreme cost containment, Pulmatrix exited the quarter with a GAAP cash and cash equivalents position of $5.8 million (down from $9.5 million at December 31, 2024), which management expects will fund operations until the Cullgen merger is finalized. This period also saw Pulmatrix focus on two main strategic moves apart from operational cuts: the attempted sale of its iSPERSE™ intellectual property and clinical programs, and its merger with Cullgen. The company openly stated, 'Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.' These pipeline programs include PUR3100 for acute migraine (an orally inhaled dihydroergotamine engineered with iSPERSE™), PUR1800 for chronic obstructive pulmonary disease (a kinase inhibitor also using the iSPERSE™ platform), and PUR1900 (an inhaled formulation of an antifungal, developed with Cipla). Development or commercial responsibility for these candidates has ended or shifted to partners, and Pulmatrix itself has no ongoing clinical trials. Regulatory milestones from past years continued to carry some legacy value. For example, the Food and Drug Administration had accepted a Phase 2 study for PUR3100 and Pulmatrix's partner Cipla is moving forward with Phase 3 for PUR1900 in India. Pulmatrix may be eligible to receive a 2% royalty on possible future non-U.S. sales of PUR1900, but this would only occur if the product is successfully commercialized—a long-term and uncertain proposition. The most critical development during the second quarter was continued progress toward completing the merger with Cullgen, a protein degrader drug development company. Pulmatrix received stockholder approval and had its registration statement declared effective by the Securities and Exchange Commission. The merger remains contingent on regulatory approvals, including from the China Security Regulatory Commission and Nasdaq. Until the deal closes, Pulmatrix is in a holding pattern, and the company highlights that any delay or failure in closing poses significant risks to its ongoing viability. Looking Ahead: Guidance and Watchpoints Pulmatrix did not provide any financial guidance or operational outlook for the next quarter or upcoming year. No revenue or earnings forecast was offered by management in the latest earnings release. The company's leadership made clear that the near-term objective is to complete the planned merger and monetize or transfer its remaining assets. Because Pulmatrix is not currently developing or selling any medications, its short-term future is heavily dependent on successful asset divestitures and getting the Cullgen deal across the finish line. Investors and observers should monitor progress toward merger closing, potential updates on the sale of iSPERSE™-related patent portfolios, and any royalty developments with former pipeline candidates. PULM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025

Acacia Research (ACTG) Q2 Revenue Up 98%
Acacia Research (ACTG) Q2 Revenue Up 98%

Globe and Mail

timean hour ago

  • Globe and Mail

Acacia Research (ACTG) Q2 Revenue Up 98%

Key Points GAAP revenue nearly doubled year over year to $51.2 million in Q2 2025, driven by newly acquired manufacturing operations, but missed the $55.0 million GAAP revenue estimate. Non-GAAP earnings per share came in at $(0.06), short of the $(0.05) non-GAAP consensus estimate; Adjusted EBITDA (non-GAAP) declined to $1.9 million from $4.1 million. Intellectual Property segment GAAP revenue dropped sharply to $0.3 million, highlighting continued volatility and reliance on one-time settlements. These 10 stocks could mint the next wave of millionaires › Acacia Research (NASDAQ:ACTG), an investment firm known for acquiring undervalued businesses across multiple sectors, released its second quarter results on August 6, 2025. The headline news from the period: GAAP revenue soared 98% from the prior-year quarter, reaching $51.2 million, primarily on the back of the Deflecto acquisition in its manufacturing business. However, The company missed analyst expectations, which had forecasted $55.0 million in GAAP revenue. Non-GAAP earnings per share (EPS) landed at $(0.06), compared with the anticipated $(0.05). Overall, the quarter reflected robust top-line growth from acquisitions. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $(0.06) $(0.05) $(0.01) (500.0%) EPS (GAAP) $(0.03) $(0.08) N/A Revenue (GAAP) $51.2 million $55.0 million $25.8 million 98.4% Total Company Adjusted EBITDA $1.9 million $4.1 million (53.7%) Free Cash Flow (Non-GAAP) $47.9 million N/A Source: Analyst estimates for the quarter provided by FactSet. Business Overview and Strategic Focus Acacia Research operates as an investment platform that acquires, manages, and seeks to unlock value in businesses across manufacturing, industrial, energy, and intellectual property. It searches for underappreciated and complex assets, with a specific emphasis on free cash flow potential and operational improvement. In recent quarters, the company has concentrated on expanding by acquisition, particularly with the addition of Deflecto to create a new manufacturing segment. Key success factors for Acacia Research include selecting the right acquisition targets, integrating them efficiently, and achieving steady cash flow. The company also leverages its partnership with Starboard Value to enhance sourcing and execution of strategic transactions. Quarter Highlights: Financial and Operational Performance The most prominent story this period was headline revenue growth, which nearly doubled year over year, with GAAP revenue increasing 98% to $51.2 million from $25.8 million in Q2 2024. This jump was primarily driven by the Manufacturing Operations segment, thanks to the second full quarter of Deflecto's contribution, generating $29.0 million in segment revenue. Energy Operations (Benchmark) delivered $15.3 million in GAAP revenue, up modestly from $14.2 million in Q2 2024, and Industrial Operations (Printronix) posted $6.6 million in GAAP revenue, up slightly from $6.3 million for Q2 2024. However, the IP segment, focused on licensing technology and patent portfolios, was a weak spot. IP revenue (GAAP) fell sharply to $0.3 million from $5.3 million in Q2 2024, reflecting a lack of new settlements or licensing income in the quarter. This high volatility is typical in IP licensing businesses, which often depend on unpredictable legal settlements. The first half of the year had been boosted by a large one-time intellectual property (IP) settlement, but the second quarter saw minimal activity. In contrast, Energy and industrial divisions showed modest revenue growth, with Energy Operations Adjusted EBITDA slightly declining and Industrial Operations Adjusted EBITDA increasing. The new manufacturing segment is now the largest by revenue, but its margin profile is slim, as shown by $1.3 million in adjusted EBITDA on $29.0 million in revenue, around a 4.4% margin. Despite strong revenue growth, profitability metrics deteriorated. Total company adjusted EBITDA (non-GAAP) was $1.9 million, a drop from $4.1 million in the prior-year period. Operated segment adjusted EBITDA (non-GAAP, excluding parent-level costs) was $6.8 million, down from $8.8 million for Q2 2024. Notably, Sales and marketing expenses for industrial and manufacturing operations increased to $3.4 million. Cash, cash equivalents, and equity securities totaled $338.2 million at period-end, up from $297.0 million at December 31, 2024, providing flexibility for future acquisitions or shareholder programs. Free cash flow (non-GAAP) was $47.9 million, aided mostly by IP settlement receipts booked earlier in the year. Total consolidated debt was $104.4 million as of June 30, 2025, with all borrowings at the operating subsidiary level and none at the parent company. Book value per share stood at $5.99, with 96.4 million shares outstanding. Segment and Product Updates, One-Time Items, and Dividend The company's diverse portfolio includes manufacturing products (Deflecto makes plastic-based goods for air distribution, transportation, and office use), industrial equipment (Printronix specializes in printing solutions), energy assets (Benchmark manages oil, gas, and natural gas liquids), and intellectual property (Acacia Research Group pursues patent-related revenue). Energy operations had an Adjusted EBITDA of $6.95 million on $15.32 million in revenue. -- while IP's contribution has proven highly variable and manufacturing's headline revenue has not yet delivered expected profit scales. Looking deeper at trends, the energy business posted stable results, reporting flat adjusted EBITDA (non-GAAP) on a modest increase in revenue. Industrial operations maintained small but positive margins. The manufacturing unit is in its initial integration phase, with management focusing on cost controls, footprint optimization, and streamlined product offerings. Despite capturing the most revenue, Deflecto's margins were slim due to ramp-up costs and higher G&A. though investors should note that first quarter results included a sizeable legal settlement in the Intellectual Property segment, distorting free cash flow and headline earnings for the current year. The company also announced a new partnership with Unchained Capital and Build Asset Management to pursue a Bitcoin-backed commercial lending product. This represents a move outside its traditional domains, and the company did not specify the scale or risk profile of the initiative in its filing. Acacia Research does not currently pay a dividend. Outlook and What to Watch Ahead Management did not provide explicit financial guidance for the remainder of fiscal 2025 or for its key segments. The leadership team reaffirmed its acquisition-driven growth strategy and noted that its strong cash position enables continued pursuit of new investments, but stopped short of giving concrete forecasts. For observers, several issues warrant attention in coming quarters. Key areas include the sustainability of revenue mix, integration of newly acquired businesses (especially Deflecto), margin recovery efforts, and the ability to generate recurring cash flow beyond large, infrequent IP settlements. Volatility in the IP segment and the still-maturing manufacturing business will likely be central drivers of earnings variability for the foreseeable future. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store